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Abstract . Numerous studies have linked the produc-
tion of increased levels of urokinase type plasminogen
activator (uPA) with the malignant phenotype . It has
also been shown that a specific cell surface receptor
can bind uPA through a domain distinct and distant
from the proteolytic domain . In an in vivo model of
invasion, consisting of experimentally modified chorio-
allantoic membrane (CAM) of a chick embryo, only
cells that concurrently expressed both uPA and a re-
ceptor for uPA, and in which the receptor was satu-
rated with uPA, were efficient in invasion . To test
whether uPA produced by one cell can, in a paracrine
fashion, affect the invasive capacity of a receptor-
expressing cell, we transfected LB6 mouse cells with
human uPA (LB6[uPA]), or human uPA-receptor
cDNA (LB6[uPAR]) . LB6(uPA) cells released into the
medium 1-2 Ploug units of human uPA per 106 cells
NUMEROUS studies have shown that proteolytic en-
zymes produced by tumor cells participate in the
degradation of components of the extracellular ma-
trix and basement membrane, thus, facilitating the invasion
ofsurroundingtissues (Dano et al ., 1985 ; Jones and DeClerc,
1980; Mignatti et al ., 1986 ; Mullins and Rohrlich, 1983 ;
Liotta and Stealer-Stevens, 1989 ; Sas et al ., 1986 ; Sloan et
al ., 1990 ; Yagel et al ., 1989) . Existing evidence suggests that
these enzymes are activated and, most likely, utilized se-
quentially (He et al ., 1989 ; Mignatti et al., 1986 ; Paranjpe
et al ., 1980, Werb et al., 1977) .
Urokinase type plasminogen activator, a serine protease,
has been linked with the malignant phenotype in experimen-
tal and naturally occurring tumors (Axelrod et al ., 1989 ;
Duffy and O'Grady 1984 ; Janicke et al ., 1990 ; Markus,
1988 ; Mira y Lopez and Ossowski, 1987 ; Ossowski and
Reich, 1983 ; Ossowski, 1988b ; Saksela and Rifkin, 1988,
Testa and Quigley, 1990 ; Unkeless et al., 1973 ; Yu and
Schultz, 1990) . It is produced and secreted by most cells in
the form of a proenzyme (Nielsen et al., 1982 ; Wun et al.,
1982) which is activated by a single proteolytic cleavage. In
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in 24 h . The LB6(uPAR) cells expressed on their sur-
face rv12,000 high affinity (Kd 1.7 x 10-10 M) uPA
binding sites per cell . Unlabeled LB6(uPA) and
"s-IUdR-labeled LB6(uPAR) cells were coinoculated
onto experimentally wounded and resealed CAMS and
their invasion was compared to that of homologous
mixtures of labeled and unlabeled LB6(uPAR) or
LB6(uPA) cells . Concurrent presence of both cell
types in the CAMS resulted in a 1.8-fold increase of
invasion of the uPAreceptor expressing cells . A four-
fold stimulation of invasion was observed when cells
were cocultured in vitro, prior to in vivo inoculation .
Enhancement of invasion was prevented in both sets of
experiments by treatment with specific antihuman uPA
antibodies, indicating that uPA was the main mediator
of the invasion-enhancing, paracrine effect on the
receptor-expressing cells .
some tumors, urokinase type plasminogen activator (uPA)'
is constitutively produced at very high levels, while in others
the enzyme level can be substantially increased by growth
factors and hormones (Dano et al ., 1985) . The natural sub-
strate of uPA, plasminogen, is a zymogen present in high
concentration in plasma and other body fluids . uPA converts
plasminogen into an active serine protease, plasmin (Reich,
1978), which is known to degrade directly several glycopro-
tein components of the basement membrane and extracellu-
lar matrix and to contribute indirectly to the degradation of
collagen (He et al ., 1989 ; Mignatti et al ., 1986 ; Paranjpe et
al ., 1980 ; Werb et al ., 1977) .
Although the localization of proteolytic enzymes on the
cell surface was suspected for many years (Chapman et al.,
1982 ; Quigley, 1976), uPA was the first enzyme for which
a cell surface receptor had been identified (Stoppelli et al.,
1985 ; Vassalli et al ., 1985) and cloned (Roldan et al ., 1990) .
We have shown that receptor-bound uPA retains its proteo-
lytic activity and that, under most conditions, the binding of
the enzyme does not induce rapid down-regulation of the
receptor-uPA complex (Cubellis et al., 1986 ; Ossowski,
1 . Abbreviations usedin thispaper : CAM, chorioallantoic membrane ; uPA,
urokinase type plasminogen activator.1988x). These properties permit the cell to concentrate a
proteolytic activity on its surface. Since invasion requires
that extracellular matrix be degraded in the immediate vicin-
ity of an advancing cell, we argued that cells equipped with
the uPA receptor, should be more effective in invasion,
provided they produced sufficientlevels ofuPA. This hypoth-
esis was tested in an in vivo model of invasion consisting of
a modified chick embryo chorioallantoic membrane (Os-
sowski, 1988x). Our results showed that the mere production
ofhigh levels ofuPA, in the absence ofsurface receptors, was
inadequate in endowing a tumor cell with maximal invasive
potential.
There is a growing recognition of the intimate reciprocal
interactions that may exist between tumor and normal
stromal cells and the role they may play in changing the
propensity oftumors to grow and invade (Basset et al., 1990;
Camps et al., 1990; Chiquet Ehrisman et al., 1989; Rand
Pritchett et al., 1989). Evidence supporting the idea that in-
teractions between tumor cellsmay lead to the emergence of
malignantly dominant subpopulations has also been ac-
cumulating (Kerbel, 1990). Moreover, it has been shown re-
cently that in coloncarcinomas the uPA receptor is produced
by tumor cells, while uPA is produced by the surrounding
fibroblasts (Pyke et al., 1991). The availability of a molecu-
lar clone of uPA and the recent cloning of the uPA receptor
afforded the first opportunity to analyze genetically whether
uPA and its receptor interact in a paracrine fashion and to
determine the functional consequences of such interaction.
Mouse LB6 cells were stably transfected with either hu-
man uPA cDNA or human uPA receptor cDNA. LB6 (uPA)
cellsproduced high levels of uPA but, due to restrictions im-
posed by the species difference (human versus mouse) (Ap-
pella et al., 1987; Estreicher et al., 1989), the secreted hu-
man uPA did not bind to the endogenous receptor of LB6
cells. LB6 (uPAR) cells expressed human uPA receptor but
did not produce detectable uPA activity, thus, the receptors
on these cells remained unoccupied. We carried out a func-
tional complementation analysis between these two cell
types using a quantitative in vivo model of connective tissue
invasion. We tested whether binding of uPA to its receptor
enhanced the invasive ability ofthe receptor-transfected cells
and whether a paracrine interaction between these two com-
ponents is operative in vivo.
Materials andMethods
Materials
COFAL-negative embryonated eggs were obtained from Spafas, Inc. (Nor-
wich, CT); DME and Geneticin from Gibco Laboratories (Grand Island,
NY); FBS from Hazleton Research Products Inc. (Lenexa, KS) ; BSA from
Armour Pharmaceutical Co. (Kankakee, II); izs-IUdR (specific activity
2,200 Ci/mmol) from New England Nuclear (Boston, MA); Enzymobeads
from BioRad Laboratories, Inc. (Richmond, CA); Trypsin from ICN Bio-
medicals, Inc. (Costa Mesa, CA) ; Carnation powdered milk (casein) from
Carnation Company, (Los Angeles, CA); Dowex -1, chloride form, Triton
X-100, and human urokinase standards from Sigma Chemical Co. (St.
Louis, MO); and chromogenic substrate for plasmin (Spectrozyme PL)
from American Diagnostica Inc. (Greenwich, CT). Recombinant, single
chain human uPA was a generous gift from Abbott Laboratories (North
Chicago, IL). Human plasminogen was purified from fresh frozen plasma
as previously described (Deutsch and Mertz, 1970); anti-human uPA IgG
(polyclonal and monoclonal) wereas previously described (Ossowski et al.,
1991). Mouse uPA was obtained from cultures of MSVtransformed 3T3
cells.
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CellLines
Mouse LB6 cells transfected with human uPA receptor cDNA under the
control ofthe SV40 promoter have been described and designated clone 19
(Roldan et al., 1990). LB6 cells expressing human uPA cDNA (LB6 clone
F) were prepared according to a previously described procedure (Nolli et
al., 1989). Both cell types were cotransfected with the pSVneo plasmid
DNA. The cells were treated with 2001pg/ml of Geneticin for 5 d every 4
to 5 wk. For clarity, throughout the manuscript we used the designation of
LB6 (uPA) for the uPA-transfected cells and LB6 (uPAR) for uPA-
receptor-transfected cells.
Methods
Quantitation of Tumor Cell Invasion of Chorioallantoic Membrane
Mesenchyme. The methods used were essentially as described previously
(Ossowski, 1988x). Briefly, LB6 (uPA) or LB6 (uPAR) cells were labeled
in culture for 20h with 0.21ACi/nil of Iu-1UdR to a specific activity of0.05
to 1.0 cpm/cell. Cells were washed extensively with DME with 5% FBS
to remove free label, resuspended at 3-4 x 105 cells per 50 ul of PBS and
inoculated on chorioallantoic membranes (CAMS) of embryos in which
artificial air sacs were created 18 to 24 h before inoculation (wounded and
resealed CAMS, see Ossowski, 1988x). Invasion was quantitated after 24 h
of incubation. CAMS were washed with PBS, excised, and both the washes
andthe CAMS were counted in the gamma counter. Thesumof these deter-
minations provided the total number ofrecovered radioactive cells used for
calculation of invasion. The CAMS were then treated with 0.05% trypsin
in 1 mM EDTAandagain countedin a gamma counter. This methodallowed
us todistinguishcellsattachedtothe surface ofCAMS, fromthose which in-
vadedthe CAMs and werethusprotected from the proteolytic action oftryp-
sin (Ossowski, 1988x). Invasion was expressed as percentoftotal recovered
cells.
Plasminogen ActivatorDetermination. We used the chromogenic sub-
strate forplasmin (Spectrozyme PL) to assay PA activity (Mira y Lopez and
Ossowski, 1987; Verheijen et al., 1982). Briefly, 10 pl ofsample to be tested
was mixed with 10514 ofTris buffer (0.1 M, pH 8.1, with0.1% Triton X-100)
and 10 1d of 0.2 mg/ml of purified human plasminogen in a 96-well, flat
bottom tray. The mixtures were incubated for 2 h at 37°C, 151el of 1 mg/ml
of the chromogenic substrate was added and the generation of color was
monitored in a multiplate reader (Dynatech Laboratories, Inc., Chantilly,
VA) at495 nm. A standard curve of human uPA (0.5-10 mU) was included
with every assay.
Identification of the Origin of Plasminogen Activator. Two methods
were used to determine the origin of uPA produced by mouse cells trans-
fected with the human uPA cDNA. Lysates and conditioned media ofthese
cells (1014) were subjected to electrophoresis onSDS-PAGE and simultane-
ous determinations of molecular weight and activity were performed using
zymography, essentially as described (Granelli-Piperno and Reich, 1978),
except the casein from powdered milk, and not fibrinogen, was used in the
indicator gels. Bands of lysis produced by the tested cells were compared
to those produced by known, standard preparations of uPA. Species origin
ofuPA was also examined by mixing cell lysates andconditioned media (-1
UofuPA/ml) with 50 gg/ml ofpurifiedmonoclonal antihuman uPA antibod-
ies, and measuring the residual uPA activity ofthese mixtures in a chromo-
genic substrate assay. While the activity produced by the LB6 (uPA) cells
was completely inhibited in this assay, a fourfold greater concentration of
this antibody did not inhibit a standard preparation of mouse uPA.
ReceptorBindingAssay. Recombinant, single chain human uPA (51tg)
was iodinated to specific activity of 4 x 107 cpm/pg protein, using En-
zymobeads and procedures recommended by the manufacturer. Unbound
iodine was removedby passage through a 1-ml prewashed Dowex-1 column.
Cells to be tested were plated in 24-well trays at 1 x 105 per well, in-
cubated overnight, washed with DME with 20 mM Hepes and 1 mg/ml of
BSA and incubated with dilutions of the radioactive uPA for 45 min at4°C
with, and without, 50-fold excessofunlabeled uPA. After three washes with
DME-Hepes-BSA the cells were extractedwith 1 N NaOH and the extracts
counted in the gamma counter. To determine receptor-bound activity, cells
were washed with DME-Hepes-BSA and then with 0.5 ml ofGlycine/HCI,
pH 3.0, for 3 min (Cubellis et al., 1986). The washes were neutralized and
tested for uPA.
Paracrine SaturationofReceptors in MixturesofLB6 (uPA) and LB6
(uPAR) Cells. We plated LB6 (uPA) cells (1 x 106) at the bottom ofa 60-
mm Cooper dish and the LB6 (uPAR) cells (8 x 105) on the inner surface
ofthe Cooper dish cover. (The cover ofthe Cooper dish is indented so that
its distance from the bottom of the dish is only 1 mm.) The bottoms and
tops were incubated separately for 20h. All cultures werethen washed with
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Cells transfected with the human uPA-receptor cDNA (clone 19 -LB6[uPAR]) or with the human uPA cDNA (clone F -LB6[uPA]), were plated in medium
with 10% FBS, grown to semiconfluency, washed once to remove serum, and incubated for 20 h in serum-free medium. Conditioned media and cell lysates were
assayed for human and mouse uPA production . (100% of the secreted uPA and 99% of the cell associated activity was inhibited by IgG against human uPA-see
Materials and Methods) . The binding of uPA to its receptor was determined using radioactive ligand ; the number of receptor sites and Kd were calculated from
Scatchard plots (see Materials and Methods) . The values given are the mean of three experiments . N.A ., not applicable . The detection limit of the chromogenic
assay is 1 Ploug mU/nil .
DME and the LB6 (uPA) (bottom ofdishes) and LB6 (uPAR) cells (covers)
were combined and incubatedin 4 ml ofDME . At 3, 7, and 20h ofcoculture
uPA activity was measured in samples of media and in the acidic (Gly-
cine/HCl, pH 3) washes of the receptor-expressing cells .
Results
Characterization of the Transfected CellLines
LB6 cells transfected with human uPA cDNA expressed
large amounts ofhuman uPA of which -60% was found in
the medium and the rest was cell associated (Table I) . The
cell-associated activity was judged to be intracellular since
it could neither be eluted by low pH treatment (Cubellis et
al ., 1986), nor degraded by prolonged exposure to trypsin
(results not shown) . The released and cell-associated uPAs
were identified as being ofhuman origin since their activity
was completely blocked by specific monoclonal anti-human
uPA IgG (results not shown) . Moreover, zymographic analy-
sis (Granelli-Piperno and Reich, 1978) showed that zones of
lysis produced by the LB6 (uPA) cells corresponded to those
produced by high molecular weight standard human uPA
(Fig. 1) . The rate of migration of cell-associated uPA was
Figure 1 . Analysis of plasminogen activator production by LB6-
(uPA) and LB6(uPAR) cells . 10 itl of conditioned media or cell
lysates of the two cell types were electrophoresed and assayed by
zymography (Granelli-Piperno and Reich, 1978) . For preparation
of conditioned medium and cell lysates see legend to Table I .
(lanes 1 and 2) LB6(uPAR) ; (lanes 3 and 4) LB6(uPA) ; (STD)
standards ; (lanes 1 and 3) conditioned media ; (lanes 2 and 4) cell
lysates . (h) Human uPA (55 and 37 kD) ; (m) mouse uPA (48 kD) .
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slightly, but consistently, faster than that of the standard . At
present, we do not have an explanation for this observation .
The analysis of uPA binding to the receptor-Tansfcted
cells revealed the presence of -12,000 high affinity (Kd of
1 .7 (0.6) x 10-'° M) specific human uPA binding sites per
cell (Table I) . The binding was found to be saturable and was
completely competed by a 50 M excess of unlabeled human
uPA (results not shown) .
Kinetics ofAaracrine Saturation ofuPA Receptors
in Co-cultures
To determine the length of time required for paracrine load-
ing ofuPA receptors, LB6 (uPA) andLB6 (uPAR) cells were
cocultivated in Cooper dishes for 3, 7, and 20 h . uPA activity
was measured in aliquots ofculture media (released activity)
and in fractions obtained by brief incubation of each type of
cells in low pH (receptor-bound activity-see Materials and
Methods) . The concentration of free uPA rose with essen-
tially linear kinetics, reaching an estimated concentration of
7 x 10-" M at 20 h . Receptor-bound uPA also rose in a
time-dependent manner, reaching at 20 h 3.3 times the level
observed at 3 h . Based on the level of releaseduPA and the
Table II. Kinetics ofuPA-receptor Filling in Co-cultures of
uPA and Receptor Expressing Cells
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The uPA-producing LB6 (uPA) and the uPA-receptor-expressing LB6 (uPAR)
cells, were plated at 1 x 106 or 8 x 10 5 cells, respectively, per Cooper dish
(see Materials and Methods) in medium with 10% FBS, incubated for 20h and,
following two washes with serum-free medium, combined so that the two cell
types faced each otherand were separated only by a 1 mm thick layer of serum-
free medium (see Materials and Methods) . At the indicated times, conditioned
medium uPA, and receptor-bound, acid releasable uPA, were measured (see
Materials and Methods) . uPA assay duplicates differed by <5% . The experi-
ment was repeated two times with similar results . Specific activity used to con-
































Cell type Mean (SD) Mean (SD) Number/cell Kd
LB6 (uPA) 1,726 (t 476) 1,047 (t 326) 0 N.A .
LB6 (uPAR) Below Below 11,700 (f 3,200) 1 .7 (t 0.6) x 10-'° M
detection detectionReceptor expressing cells LB6(uPAR) or human uPA producing cells (LB6-
[uPA]) were labeled in culture with 0 .2 uCi/ml of 'z'-IUdR for 24 h . Before
inoculation, 1 .5 x 10' labeled cells were combined with 3 x 10' unlabeled
receptor or uPA expressing cells and inoculatedon CAMS in 50 Al of PBS . In-
vasion of CAMs was measured 24 h postinoculation (for details see Materials
and Methods and Ossowski, 1988a) . The data shown are a summary of two
identical experiments ; each group included 12 embryos . Analysis of variance
(Systat Statistics) gave a p value of0.063 . Thep value for uPA + uPAR vs .
uPARwas 0.032, for uPA + uPARvs . uPA was 0.046, and for uPA vs . uPAR
was 0.698 .
established Kd (Table I), -33% of the receptors would be
expected to be filled with uPA after 20 h of co-cultivation.
The measured level of receptor-bound uPA (Table II) indi-
cated that a somewhat greater actual receptor occupancy
may have been achieved .
Interaction between uPA anduPA Receptorproducing
Cells In lrvo
To test whether the presence in the CAM ofuPA secreting
cells would affect the efficiency of invasion we used a quan-
titative in vivo model of tumor invasion (Ossowski, 1988a) .
In this model 9-d-old embryos with artificially wounded
CAMS were incubated until the wounds were sealed (usually
24-30 h) by a layer of fibroblasts resulting in structures par-
tially resistant to tumor cell invasion . The model was
adapted to allow a measurable, but low level, invasion by the
receptor-transfected cells by reducing the time between
Figure 2. Enhancement of
invasion of LB6(uPAR) cells
by LB6(uPA) cells ; coculture
before CAM inoculation . Re-
ceptor-expressing cells LB6-
(uPAR) or uPA-producing LB6-
(uPA) cells were labeled in
culture with ' 25-IUdR, mixed
with an equal number of un-
labeled cells of either the
homologous or the heterolo-
gous type, and incubated for
an additional 20 h . All cells
were detached, washed, and
each cell mixture (4 x 105
cells) was inoculated onto 10
CAMs wounded 18 h earlier,
and incubated at 37° for 24 h,
at which time invasion was
quantitated (see Materials and Methods) . The difference between
groups was statistically significant, p = 0.006 by analysis of vari-
ance ; mixed cells vs . uPAR, p = 0.004, mixed cells vs . uPA, 0.008
anduPAR vs . uPA cells, p = 0.9 . R.uPA, mixture of labeled recep-
tor cells and unlabeled uPA cells ; R .R, mixture of labeled and unla-
beled receptor cells ; uPA.uPA, mixture of labeled and unlabeled
uPA cells .
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Mixtures (5 x 104 cells each) of receptor-expressing and uPA-producing cells
were co-cultured overnight in 24-well trays inDME with 10% FBS, detached,
washed extensively, and incubated in suspension (1 x 101 cells/ml) with 50
Wg/ml of anti-human-uPA IgG for 1 h at 37°C . The cells were washed three
times and incubated for 30 minat 37°C with 100pg/ml ofhuman plasminogen .
The amount ofplasmin generated was measured using a chromogenic substrate
(see Materials and Methods) . The positive control (without antibodies, with
plasminogen) generated 1 .6OD495 U/h .
wounding and inoculation . LB6 (uPAR) cells were labeled
in culture with tz 5-IUdR, and coinoculated with unlabeled
LB6 (uPA) cells on the sealed CAMs . LabeleduPAR oruPA
cells, mixed with homologous, unlabeled cells were used as
controls . Results in Table III indicate that the coinoculation
of uPA-producing cells leads to an enhancement of invasion
by the receptor-expressing cells . Qualitatively similar re-
sults, showing an enhancement of invasion from 1.5- to 2.1-
fold, were observed in eight additional experiments (results
not shown) .
Since the level of receptor saturation is dependent on the
ligand concentration, and since under conditions of continu-
ous uPA production, ligand concentration rises with time
(see Table II), we tested whether receptor cells cocultured
with uPA-producing cells for 20 h before inoculation on the
CAMS would invade more efficiently . In this experiment the
receptor cells were labeled with 125-IUdR before coculture.
Control mixtures included labeled and unlabeled receptor
cells and labeled and unlabeled uPA-producing cells . This
approach produced a fourfold (p = 0.006) enhancement of
receptor-expressing cell invasion by the uPA-producing cells
(Fig . 2) .
To test whether the enhancement of invasion was mediated
solely via a transfer of uPA from an enzyme producing cell
to a receptor expressing cell (paracrine mechanism) we car-
Table V. The E ffect ofAnti-uPA Antibodies on Invasion
Inhibition of invasion (%)
Experiment Mean (SD) P
1
￿
69 .8 (±26.0) 0.013
2
￿
85 .8 (±12.0) 0.008
LB6(uPAR) cells were labeled in culture with 'i'-IUdR for 20 h, detached,
mixed with an equal number of LB6(uPA) cells, and further incubated in
60-mm dishes for 24 h . The following preimmune or anti-human uPA IgGs
were used : in experiment 1, in which 18 embryos were used, 300 pg of
monoclonals and 1 mg of rabbit polyclonals added to cells immediately before
inoculation and also added to CAMs 1 h before inoculation ; in experiment 2,
in which 16 embryos were used, mAbs (50 ug/ml) were added to cells for the
20 h of in vitro coculture and also added to the inoculum . Invasion of cells
treated with similar concentrations of normal IgG (mouse or rabbit) was con-
sidered 100% and used to calculate percent inhibition . The significance of the
difference between the control and antibody treated groups (p values) was
tested using the r test .
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Table III . Stimulation ofReceptor-expressing Cells




Invasion ofCAMS Antibody Plasminogen uPA
Cells on CAM Radioactivity (% of total recovered) treatment in uPA assay (% control)
Labeled Unlabeled Mean (SD) Median Range - + 100.0
_ - 0.7
LB6(uPAR) LB6(uPAR) 5.4 (±3.3) 4.4 (2.3-12.3) + + 1 .4
LB6(uPA) LB6(uPA) 5.6 (f3.7) 4.4 (1.9-13.9) + - 1 .7
OB6(uPAR) LB6(uPA) 10.0 (±3.8) 11 .5 (4.6-13.6)ried out the invasion assays in the presence of specific inhibi-
tory antihuman uPA antibodies. This antibody was capable
of inhibiting receptor-bound uPA activity (see TableIV), in-
dicating that the epitope it recognized was not hindered by
binding to the receptor. Inclusion of the inhibitory antibod-
ies in both experimental designs (Table III and Fig. 2)
resulted in a significant inhibition of invasion (Table V).
Discussion
Using a functional complementation analysis we showed that
uPA produced by one cell can, by a paracrine in vivo interac-
tion, modulate the invasive potential of a uPAreceptor-ex-
pressing tumor cell. This result is of particular interest for
two reasons. First, it confirmed our previous observations
which implicated uPA receptor in the enhancement of uPA-
dependent invasion of CAMS (Ossowski, 1988a) . Second, to
the best ofour knowledge, it represents the few documented
cases in which a known mediator affected the malignant
potential of tumor cells in vivo via a paracrine interaction.
Although the mechanism of enhancement of invasion by
receptor-bound uPA is not yet understood, it may function
by focusing the proteolytic activity on the cell surface. This
notion is supported by the findings that plasmin generation
on the surface ofcellsis more effective than in solution (Plow
et al., 1986). One possible explanation for this effect may be
found in the observation (Quax et al., 1991) that receptor-
bound pro-uPA (the form commonly released by most cells)
may be more susceptible to activation by plasmin. Other
mechanisms responsible for the enhanced proteolysis by the
receptor-bound uPA are currently being investigated.
The analysis ofparacrine interactions between tumor cells
and their role in the enhancement of malignancy was made
possible by the availability of the molecular clones of uPA
and its receptor and an in vivo model of invasion, which
couldbe adapted to accommodate cells with greatly differing
invasive potentials (Ossowski, 1988a) . We have previously
shown that under the most stringent conditions of the CAM
model only highly malignant cells yielded measurable inva-
sion (Ossowski, 1988a) . These cells were found to produce,
in addition to uPA, at least one other proteolytic enzyme be-
longing to the metalloproteinase family (Ossowski, L.,
manuscript in preparation) . However, it was possible, by
reducing the stringency of resistance of the CAM to inva-
sion, to assess quantitatively even cells with marginal inva-
sive potential such as the LB6 (uPAR) cells.
We found that inoculated individually, the transfected
cells, evenunder conditions oflow stringency, produced very
low level of CAM invasion (Table III) . Coinoculation of the
two cell types enhanced the invasion of the receptor-
expressing cells 1.8-fold. The relatively small enhancement
was not unexpected since, although the LB6 (uPAR) bind
uPA with high affinity (Kd 1.7 x 10-'° M; Table I), the
number of their plasma membrane binding sites (11,700) is
lower(Table I) than that reported for highly malignant tumor
cells ranging from 40,000 to 100,000 (Ossowski, 1988a;
Schlechte et al ., 1989). Also, Schlechte et al. (1989) have
shown that the ability to invade in an in vitro model was cor-
related with the number of surface uPA receptors. Moreover,
it should be kept in mind that coinoculation of the two cell
types on the CAM, in which relatively small number ofcells
in suspension (3-4 x 1(Y) encounter relatively large areas
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of tissue, may not accurately represent the topography that
exists in a primary tumor. This may reduce the effective con-
centration ofuPA in the vicinity of receptor-expressing cells
and thus reduce the level of receptor saturation by the en-
zyme. In spite of this relative inefficiency of the system, the
results clearly show that uPA producedby one cell can be uti-
lized, in a paracrine fashion, to potentiate the invasive ability
ofanother cell. The fact that in experiments in which the two
cell types were cocultured before inoculation the potentia-
tion of invasion was much greater (Fig. 2), gives additional
support to the notion that during the brief period (24 h) in
the CAM, cell interactions may be less than optimal and that
in a naturally developing tumor the paracrine effects may be
of much greater magnitude.
We used inhibitory anti-human uPA IgGs to positively
identify uPA as themediator ofthe observed enhancing effect
on invasion. This treatment, which specifically interrupted
theparacrine interaction, greatly reduced the potentiation by
LB6 (uPA) cells (Table V), implicating uPA as the main
mediator of the effect. The magnitude of the inhibition indi-
cated that no other paracrine signals, important for invasion
of connective tissue, were exchanged between the two cell
types.
Overall, using a functional complementation analysis of
genetically engineered cells, we proved that specific para-
crine interactions, involving uPA and its receptor, lead to in-
creased tumor invasion in vivo. The significance of this
finding is underscored by the recent observation showing
that, in colon carcinomas in man, uPA and its receptor are
produced by distinct populations of cells (Pyke et al., 1991),
suggesting that interactions of the kind described here may
be operative and necessary for the expression of the full
malignant potential of tumors.
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